ARTICLE | Clinical News
Pracinostat regulatory update
August 8, 2016 7:00 AM UTC
FDA granted breakthrough therapy designation to MEI’s pracinostat in combination with azacitidine to treat acute myelogenous leukemia (AML) in patients ages >=75 or who are otherwise unfit for intensi...